GREENFIELD, Ind., Dec. 19, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts at 3:00 p.m. PST (6:00 PM EST).
A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website. A replay will be available for approximately 30 days.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Investor Contact: Katy Grissom (317) 273-9284 kathryn.grissom@elancoah.com
Media Contact: Colleen Parr Dekker (317) 989-7011 colleen_parr_dekker@elancoah.com
| Last Trade: | US$12.82 |
| Daily Change: | 0.86 7.19 |
| Daily Volume: | 7,495,114 |
| Market Cap: | US$6.340B |
February 25, 2025 February 25, 2025 November 15, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
